You are not currently logged in.
Access your personal account or get JSTOR access through your library or other institution:
Ampicillin, Sulbactam, and Rifampin Combination Treatment of Experimental Methicillin-Resistant Staphylococcus aureus Endocarditis in Rabbits
Henry F. Chambers, Marinka Kartalija and Merle Sande
The Journal of Infectious Diseases
Vol. 171, No. 4 (Apr., 1995), pp. 897-902
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/30132178
Page Count: 6
Preview not available
Ampicillin or amoxicillin at 625-800 mg/kg/day, in combination with a /ft-lactamase inhibitor, each is as effective as vancomycin in animal models of methicillin-resistant Staphylococcus aureus endocarditis. Studies were done to determine whether the addition of rifampin would permit lowering the dose of ampicillin into the range recommended for use in humans without loss of efficacy. The efficacy of ampicillin/sulbactam (300/150 or 150/75 mg/kg/day intramuscularly, in three divided doses) in combination with rifampin (5 mg/kg intramuscularly, three times daily) was compared with that of vancomycin (25 mg/kg intravenously, twice daily, or 30 mg/kg intramuscularly, three times daily) in the rabbit model of methicillin-resistant S. aureus aortic valve endocarditis. Neither ampicillin/sulbactam nor rifampin alone was effective. The ampicillin/sulbactam/rifampin regimen was as effective as vancomycin. This regimen may be an alternative to vancomycin in treatment of methicillin-resistant S, aureus infections.
The Journal of Infectious Diseases © 1995 Oxford University Press